Rasi Bhadramani/iStock via Getty Images
Sarepta Therapeutics (NASDAQ:SRPT) was upgraded to Neutral from Underweight at J.P. Morgan as it sees FDA's Elevidys hold removal recommendation in ambulatory patients as a clear win.
The company's rating was also raised at Oppenheimer to Outperform from Perform, as analysts at